Development of the novel biologically targeted anticancer agent gefitinib: Determining the optimum dose for clinical efficacy

Clinical Cancer Research

Volumn 10, Issue 14, 2004, Pages 4607-4613

  Wolf, Michael ^a   Swaisland, Helen ^a   Averbuch, Steven ^a,b  

^a ASTRAZENECA   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE;

ACNE; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BIOLOGICAL THERAPY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CARCINOMA; DIARRHEA; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRY SKIN; HEAD AND NECK CARCINOMA; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; NAUSEA; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; RASH; REVIEW; SQUAMOUS CELL CARCINOMA; VOMITING;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KERATINOCYTES; LUNG NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 3242658931     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0058     Document Type: Review

References (31)

1. Rowinsky EK. The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents. Drugs 2000;60(Suppl 1):1-14.
2. Fox E, Curt GA, Balis FM. Clinical trial design for target-based therapy. Oncologist 2002;7:401-9.
3. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241-50.
4. Rusch V, Baselga J, Cordon-Cardo C, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993;53:2379-85.
5. Swaisland H, Laight A, Stafford L, et al. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clin Pharmacokinet 2001;40:297-306.
6. Nakagawa K, Tamura T, Negoro S, et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumours. Ann Oncol 2003;14:922-30.
7. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002;20:2240-50.
8. Herbst RS, Maddox AM, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002;20:3815-25.
9. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002;20:4292-302.
10. AstraZeneca, Macclesfield, UK. Data on file. Unpublished data, 2004.
11. Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995;12:199-220.
12. LoRusso PM, Herbst RS, Rischin D, et al. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res 2003;9:2040-8.
13. Threadgill DW, Dlugosz AA, Hansen LA, et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science (Wash DC) 1995;269:230-4.
14. Miettinen PJ, Berger JE, Meneses J, et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature (Lond) 1995;376:337-41.
15. Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002;20:110-24.
16. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-46.
17. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. JAMA 2003;290:2149-58.
18. Fukuoka M, Kris M, Giaccone G, et al. Phase II trials of gefitinib ('Iressa', ZD1839): rapid and durable objective responses in patients with advanced non-small-cell lung cancer (IDEAL 1 and IDEAL 2). Lung Cancer 2003;41(Suppl 2):S247-8.
19. McKillop D, Stephens TC, Partridge EA, et al. The distribution of gefitinib ('Iressa', ZD1839) into mouse xenograft tumours. Poster A100 presented at the AACR-NCI-EORTC, Boston, MA, USA, November 17-21, 2003. Clin Cancer Res 2003;9(Suppl):6093S
20. Baselga J, Albanell J, Ruiz A, et al. Phase II and tumor pharmacodynamic study of gefitinib (ZD1839) in patients with advanced breast cancer. Proc Am Soc Clin Oncol 2003;22:7.
21. Rojo F, Tabernero J, Van Cutsem E, et al. Pharmacodynamic studies of tumor biopsy specimens from patients with advanced gastric carcinoma undergoing treatment with gefitinib (ZD1839). Proc Am Soc Clin Oncol 2003;22:191.
22. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18:904-14.
23. Birner P, Oberhuber G, Stani J, et al. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 2001;7:1669-75.
24. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
25. Natale RB, Shak S, Aronson N, et al. Quantitative gene expression in non-small cell lung cancer from paraffin-embedded tissue specimens: predicting response to gefitinib, an EGFR kinase inhibitor. Proc Am Soc Clin Oncol 2003;22:190.
26. Bailey LR, Kris M, Wolf M, et al. Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib ('Iressa', ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL 1 and 2. Proc Am Assoc Cancer Res 2003;44(Ed 2):1362.
27. Ciardiello F, Tortora G. Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 2003;39:1348-54.
28. Forsythe B, Faulkner K. Safety and tolerability of gefitinib ('Iressa', ZD1839) in advanced NSCLC: overview of clinical experience. Poster P327 presented at the ERS, Vienna, Austria, September 27-October 1, 2003. Eur Respir J 2003;22(Suppl 45):32s.
29. Fukuoka M, Kris M, Giaccone G, et al. Phase II trials of gefitinib ('Iressa', ZD1839): rapid and durable objective responses in patients with advanced non-small-cell lung cancer (IDEAL 1 and IDEAL 2). Poster presented at the WCLC, Vancouver, Canada, August 10-14, 2003. Lung Cancer 2003;41(Suppl 2):S247.
30. Natale R, Skarin A, Maddox A, et al. Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2. Poster 1167 presented at the ASCO, Orlando, FL, May 18-21, 2002. Proc Am Soc Clin Oncol 2002;21:292a.
31. Herbst R. Targeting the epidermal growth factor receptor: prognostic and clinical implications. Eur J Cancer Suppl 2003;1:9-15.